Lilly In Collaboration To Screen NIH Pharmaceuticals Collection, Make Pharmacology Data Public
Executive Summary
Repurposing opportunities are unlikely in this NCATS/Lilly project, which has the loftier goal of furthering understanding of how small molecule drugs actually work in complex human systems in order to improve drug development for the entire “research universe.”
You may also be interested in...
Clinical Trial Data Release: Be Careful What You Wish For, Industry Exec Says
Some advocates and researchers say that data availability could inform repurposing opportunities for products, but a GSK exec cautions that it could just as easily bring a flood of confusing information.
NIH Drug Repurposing Program Produces Surprise Overlaps
Crowdsourcing among researchers produces several applications proposing to test a few compounds in the NCATS repurposing library for use in multiple new indications, which officials did not expect.
NIH Royalties For Pfizer, AstraZeneca, Lilly Drugs Remain Open Question In Repurposing Initiative
With collaborative research agreement templates that include many of the details for a licensing agreement, royalties will be the major issue to be resolved if researchers develop new IP for one of the firm’s abandoned compounds.